Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Big Pharma’s Unlikely Price Pledge Leader

Executive Summary

Allergan is taking a page from Big Pharma’s strategy two decades ago to fend off efforts at direct price regulation by pledging restraint on price increases. The differences in the pledge – and the image of the pledge maker – are instructive.


Related Content

Who's Promised What: A Guide To Pharma Drug Pricing Pledges
US Branded Drug Invoice Price Increases Moderate In 2016
US Branded Drug Invoice Price Increases Moderate In 2016
Just Trust Me: Most Firms Unwilling To Publicly Pledge Pricing Restraint
US Brand Drug Price Inflation Slowing As Elections Approach
Clinton Transition Co-Chair Tanden Offers Themes For A Drug Pricing Bill In 2017
Formalizing 'Name And Shame': New Strategy To Rein In Price Increases
The Clinton Drug Price Board, 23 Years Later
Allergan's Price Reform Pledge: Will Others Follow?
The Fall Of Pfizergan: The Beginning, The End And Everything In Between


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts